FindTrial
Sign In

Study on Lignocaine Infusion for Chronic Persistent Nerve Pain

Effect of Lignocaine infusion in Management of Chronic Neuropathic Pain Single Arm Interventional Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/05/087759
Enrollment
100
Registered
2025-05-28
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G540- Brachial plexus disorders Health Condition 2: G560- Carpal tunnel syndrome Health Condition 3: G577- Causalgia of lower limb Health Condition 4: G890- Central pain syndrome Health Condition 5: G563- Lesion of radial nerve Health Condition 6: G562- Lesion of ulnar nerve Health Condition 7: G541- Lumbosacral plexus disorders Health Condition 8: G571- Meralgia paresthetica Health Condition 9: G546- Phantom limb syndrome with pain Health Condition 10: G575- Tarsal tunnel sy

Interventions

Intervention1: Lignocaine infusion in Management of Chronic Neuropathic Pain: After informed and written consent, patients who met with inclusion criteria will be given IV bolus of 1.5mg/kg(3-5 min)li

Sponsors

NIL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed as having neuropathic pain S-LANSS (neuropathic pain score)more than 12/24 indicates neuropathic pain Diabetic neuropathy,Post herpetic neuralgia,Post amputation pain,CRPS,Traumatic plexus lesion,Peripheral nerve injury NRS - more than 4 (on a 0 10 point numerical rating scale) inspite of conservative medications for more than 3 months

Exclusion criteria

Exclusion criteria: Patients with cardiac disease (conduction abnormalities,CHF,resting HR less than 50 per min), liver disease, CKD,Allergy to Local Anesthetic,Females who are pregnant,breast feeding,Cognitive impairment

Design outcomes

Primary

MeasureTime frame
Reduction in pain intensity measured by NRS (Numerical Rating Scale) over time, particularly from baseline to the end of the 4 weekly infusions and during follow-up up to 8 weeksTimepoint: 8 weeks post intervention—

Secondary

MeasureTime frame
hange in S-LANSS score (a tool used to assess neuropathic pain features) pre- and post-infusion. Patient Global Impression of Change (PGIC) scores post-treatment. Incidence of side effects such as dizziness, nausea, allergic reactions, changes in HR,BP, numbness, tingling, or seizures during and after infusions.Timepoint: 8 weeks post intervention—

Countries

India

Contacts

Public ContactDrEdward Johnson

Kanyakumari Government Medical College and Hospital

edwardjohnson2310@gmail.com9443392974

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026